Search

Your search keyword '"Gregory, Gareth"' showing total 307 results
Start Over Author "Gregory, Gareth"
307 results on '"Gregory, Gareth"'

3. Mosunetuzumab monotherapy is active and tolerable in patients with relapsed/refractory diffuse large B-cell lymphoma

Author

Bartlett, Nancy L., Assouline, Sarit, Giri, Pratyush, Schuster, Stephen J., Cheah, Chan Y., Matasar, Matthew, Gregory, Gareth P., Yoon, Dok Hyun, Shadman, Mazyar, Fay, Keith, Yoon, Sung-Soo, Panizo, Carlos, Flinn, Ian, Johnston, Anna, Bosch, Francesc, Sehn, Laurie H., Wei, Michael C., Yin, Shen, To, Iris, Li, Chi-Chung, Huang, Huang, Kwan, Antonia, Penuel, Elicia, and Budde, Lihua E.

Published
2023
Full Text
View/download PDF

5. A phase 1/2 study of favezelimab in combination with pembrolizumab for heavily pretreated anti–PD-1–refractory classical Hodgkin lymphoma (cHL): An updated analysis.

Author

Timmerman, John, primary, Lavie, David, additional, Johnson, Nathalie A., additional, Avigdor, Abraham, additional, Peter, Borchmann, additional, Andreadis, Charalambos, additional, Bazargan, Ali, additional, Gregory, Gareth P., additional, Keane, Colm, additional, Torzan, Inna, additional, Vucinic, Vladan, additional, Zinzani, Pier Luigi, additional, West, Rachel Marceau, additional, Pillai, Pallavi, additional, Marinello, Patricia, additional, and Herrera, Alex Francisco, additional

Published
2024
Full Text
View/download PDF

6. Integrated clinical and genomic evaluation of guadecitabine (SGI-110) in peripheral T-cell lymphoma

Author

Wong, Jonathan, Gruber, Emily, Maher, Belinda, Waltham, Mark, Sabouri-Thompson, Zahra, Jong, Ian, Luong, Quinton, Levy, Sidney, Kumar, Beena, Brasacchio, Daniella, Jia, Wendy, So, Joan, Skinner, Hugh, Lewis, Alexander, Hogg, Simon J., Vervoort, Stephin, DiCorleto, Carmen, Uhe, Micheleine, Gamgee, Jeanette, Opat, Stephen, Gregory, Gareth P., Polekhina, Galina, Reynolds, John, Hawkes, Eliza A., Kailainathan, Gajan, Gasiorowski, Robin, Kats, Lev M., and Shortt, Jake

Published
2022
Full Text
View/download PDF

8. Pembrolizumab plus dinaciclib in patients with hematologic malignancies: the phase 1b KEYNOTE-155 study

Author

Gregory, Gareth P., Kumar, Shaji, Wang, Ding, Mahadevan, Daruka, Walker, Patricia, Wagner-Johnston, Nina, Escobar, Carolina, Bannerji, Rajat, Bhutani, Divaya, Chang, Julie, Hernandez-Ilizaliturri, Francisco J., Klein, Andreas, Pagel, John M., Rybka, Witold, Yee, Andrew J., Mohrbacher, Anne, Huang, Mo, Farooqui, Mohammed, Marinello, Patricia, and Quach, Hang

Published
2022
Full Text
View/download PDF

9. Infection risk and antimicrobial prophylaxis in bendamustine‐treated patients with indolent non‐Hodgkin lymphoma: An Australasian Lymphoma Alliance study.

Author

Manos, Kate, Churilov, Leonid, Grigg, Andrew, Di Ciaccio, Pietro, Wong, Jonathan, Chandra Sekaran, Usha, Wight, Joel, Goh, Zhong, Jina, Hayden, Butler, Llewyn, Yannakou, Costas K., Hamad, Nada, Gregory, Gareth P., Gangatharan, Shane, Cochrane, Tara, Hawkes, Eliza A., and Lasica, Masa

Subjects
NON-Hodgkin's lymphoma, HERPES simplex virus, LYMPHOMAS, OPPORTUNISTIC infections, MYCOSES
Abstract

Summary: Infection and lymphopenia are established bendamustine‐related complications. The relationship between lymphopenia severity and infection risk, and the role of antimicrobial prophylaxis, is not well described. This multicentre retrospective study analysed infection characteristics and antimicrobial prophylaxis in 302 bendamustine‐treated indolent non‐Hodgkin lymphoma patients. Lymphopenia (<1 × 109/L) was near universal and time to lymphocyte recovery correlated with cumulative bendamustine dose. No association between lymphopenia severity and duration with infection was observed. Infections occurred in 44% of patients (50% bacterial) with 27% hospitalised; 32% of infections occurred ≥3 months post bendamustine completion. Infection was associated with obinutuzumab and/or maintenance anti‐CD20 therapy, prior therapy and advanced stage. Twenty‐four opportunistic infections occurred in 21 patients: ten varicella zoster virus (VZV), seven herpes simplex virus (HSV), one cytomegalovirus, one progressive multifocal leucoencephalopathy, one nocardiosis, one Pneumocystis jiroveci pneumonia (PJP) and three other fungal infections. VZV/HSV and PJP prophylaxis were prescribed to 42% and 54% respectively. Fewer VZV/HSV infections occurred in patients receiving prophylaxis (HR 0.14, p = 0.061) while PJP prophylaxis was associated with reduced risk of bacterial infection (HR 0.48, p = 0.004). Our study demonstrates a significant infection risk regardless of lymphopenia severity and supports prophylaxis to mitigate the risk of early and delayed infections. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

13. Marginal zone lymphomas: a consensus practice statement from the Australasian Lymphoma Alliance.

Author

Lasica, Masa, Anderson, Mary A., Boussioutas, Alex, Gregory, Gareth P., Hamad, Nada, Manos, Kate, McKelvie, Penny, Ng, Michael, Campbell, Belinda, Palfreyman, Emma, Salvaris, Ross, Weinkove, Robert, Wight, Joel, Opat, Stephen, and Tam, Constantine

Subjects
CONSENSUS (Social sciences), MEDICAL protocols, NON-Hodgkin's lymphoma, CANCER relapse, TREATMENT effectiveness, SYMPTOMS
Abstract

Marginal zone lymphomas (MZLs) are a rare, indolent group of non‐Hodgkin lymphomas with different diagnostic, genetic and clinical features and therapeutic implications. The most common is extranodal MZL of mucosa‐associated lymphoid tissue, followed by splenic MZL and nodal MZL. Patients with MZL generally have good outcomes with long survival rates but frequently have a relapsing/remitting course requiring several lines of therapy. The heterogeneous presentation and relapsing course present the clinician with several diagnostic and therapeutic challenges. This position statement presents evidence‐based recommendations in the setting of Australia and New Zealand. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

16. Australia and New Zealand consensus position statement: use of COVID‐19 therapeutics in patients with haematological malignancies

Author

Campbell, Ashlea, primary, Teh, Benjamin, additional, Mulligan, Stephen, additional, Ross, David M., additional, Weinkove, Robert, additional, Gilroy, Nicole, additional, Gangatharan, Shane, additional, Prince, Henry Miles, additional, Szer, Jeff, additional, Trotman, Judith, additional, Lane, Steven, additional, Dickinson, Michael, additional, Quach, Hang, additional, Enjeti, Anoop K., additional, Ku, Matthew, additional, Gregory, Gareth, additional, Hapgood, Gregory, additional, Ho, Phoebe Joy, additional, Cochrane, Tara, additional, Cheah, Chan, additional, Greenwood, Matthew, additional, Latimer, Maya, additional, Berkahn, Leanne, additional, Wight, Joel, additional, Armytage, Tasman, additional, Diamond, Peter, additional, Tam, Constantine S., additional, and Hamad, Nada, additional

Published
2023
Full Text
View/download PDF

17. Mosunetuzumab Safety Profile in Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma: Clinical Management Experience from a Pivotal Phase I/II Trial

Author

Matasar, Matthew, primary, Bartlett, Nancy L., additional, Shadman, Mazyar, additional, Budde, Lihua E., additional, Flinn, Ian, additional, Gregory, Gareth P., additional, Kim, Won Seog, additional, Hess, Georg, additional, El-Sharkawi, Dima, additional, Diefenbach, Catherine S., additional, Huang, Huang, additional, To, Iris, additional, Parreira, Joana, additional, Wu, Mei, additional, Kwan, Antonia, additional, and Assouline, Sarit, additional

Published
2023
Full Text
View/download PDF

18. A novel CDK9 inhibitor increases the efficacy of venetoclax (ABT-199) in multiple models of hematologic malignancies

Author

Phillips, Darren C., Jin, Sha, Gregory, Gareth P., Zhang, Qi, Xue, John, Zhao, Xiaoxian, Chen, Jun, Tong, Yunsong, Zhang, Haichao, Smith, Morey, Tahir, Stephen K., Clark, Rick F., Penning, Thomas D., Devlin, Jennifer R., Shortt, Jake, Hsi, Eric D., Albert, Daniel H., Konopleva, Marina, Johnstone, Ricky W., Leverson, Joel D., and Souers, Andrew J.

Published
2020
Full Text
View/download PDF

19. Australia and New Zealand consensus position statement: use of COVID‐19 therapeutics in patients with haematological malignancies.

Author

Campbell, Ashlea, Teh, Benjamin, Mulligan, Stephen, Ross, David M., Weinkove, Robert, Gilroy, Nicole, Gangatharan, Shane, Prince, Henry Miles, Szer, Jeff, Trotman, Judith, Lane, Steven, Dickinson, Michael, Quach, Hang, Enjeti, Anoop K., Ku, Matthew, Gregory, Gareth, Hapgood, Gregory, Ho, Phoebe Joy, Cochrane, Tara, and Cheah, Chan

Subjects
THERAPEUTIC use of monoclonal antibodies, EVALUATION of medical care, DRUG efficacy, COVID-19, COMMUNICABLE diseases, HEMATOLOGY, COVID-19 vaccines, ANTIVIRAL agents, CANCER patients, PREVENTIVE health services, SEVERITY of illness index, MEDICAL protocols, VACCINE effectiveness, PRE-exposure prophylaxis, PATIENT monitoring, HEMATOLOGIC malignancies, INTERPROFESSIONAL relations, CRITICAL care medicine, DISEASE duration, ISOLATION (Hospital care), DISEASE management, COMORBIDITY, EARLY medical intervention
Abstract

Despite widespread vaccination rates, we are living with high transmission rates of SARS‐CoV‐2. Although overall hospitalisation rates are falling, the risk of serious infection remains high for patients who are immunocompromised because of haematological malignancies. In light of the ongoing pandemic and the development of multiple agents for treatment, representatives from the Haematology Society of Australia and New Zealand and infectious diseases specialists have collaborated on this consensus position statement regarding COVID‐19 management in patients with haematological disorders. It is our recommendation that both patients with haematological malignancies and treating specialists be educated regarding the preventive and treatment options available and that patients continue to receive adequate vaccinations, keeping in mind the suboptimal vaccine responses that occur in haematology patients, in particular, those with B‐cell malignancies and on B‐cell‐targeting or depleting therapy. Patients with haematological malignancies should receive treatment for COVID‐19 in accordance with the severity of their symptoms, but even mild infections should prompt early treatment with antiviral agents. The issue of de‐isolation following COVID‐19 infection and optimal time to treatment for haematological malignancies is discussed but remains an area with evolving data. This position statement is to be used in conjunction with advice from infectious disease, respiratory and intensive care specialists, and current guidelines from the National COVID‐19 Clinical Evidence Taskforce and the New Zealand Ministry of Health and Cancer Agency Te Aho o Te Kahu COVID‐19 Guidelines. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

20. Rationally designed chimeric PI3K-BET bromodomain inhibitors elicit curative responses in MYC-driven lymphoma

Author

Oh, Danielle H., primary, Ma, Xiao, additional, Hogg, Simon J., additional, He, Jackson, additional, Kearney, Conor, additional, Brasacchio, Daniella, additional, Susanto, Olivia, additional, Maher, Belinda, additional, Jennings, Ian G., additional, Newbold, Andrea, additional, Fraser, Peter, additional, Gruber, Emily, additional, Kats, Lev M., additional, Gregory, Gareth P., additional, Johnstone, Ricky W., additional, Thompson, Philip E., additional, and Shortt, Jake, additional

Published
2023
Full Text
View/download PDF

21. P1126: PHASE 1B/2A STUDY OF AZD4573 (CDK9I) AND ACALABRUTINIB IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA (R/R DLBCL)

Author

Strati, Paolo, primary, Morschhauser, Franck, additional, Danilov, Alexey, additional, Cheah, Chan, additional, Shah, Harsh, additional, Jurczak, Wojciech, additional, Olabode, Damilola, additional, Meyer, Stefanie, additional, Lim Yoon, Jeong, additional, Arduini, Serena, additional, Saeh, Jamal, additional, Olsson, Richardp, additional, and Gregory, Gareth, additional

Published
2023
Full Text
View/download PDF

22. P1068: UPDATED RESULTS FROM AN OPEN-LABEL PHASE 1/2 STUDY OF FAVEZELIMAB IN COMBINATION WITH PEMBROLIZUMAB IN PATIENTS WITH RELAPSED OR REFRACTORY CLASSICAL HODGKIN LYMPHOMA AFTER ANTI–PD-1 TREATMENT

Author

Timmerman, John, primary, Lavie, David, additional, Johnson, Nathalie, additional, Avigdor, Abraham, additional, Borchmann, Peter, additional, Andreadis, Charalambos, additional, Bazargan, Ali, additional, Gregory, Gareth, additional, Keane, Colm, additional, Tzoran, Inna, additional, Vucinic, Vladan, additional, Luigi Zinzani, Pier, additional, Marceau West, Rachel, additional, Pillai, Pallavi, additional, Marinello, Patricia, additional, and Herrera, Alex F., additional

Published
2023
Full Text
View/download PDF

23. P1065: UPDATED RESULTS FROM AN OPEN-LABEL PHASE 1/2 STUDY OF FAVEZELIMAB IN COMBINATION WITH PEMBROLIZUMAB IN PATIENTS WITH ANTI–PD-1–NAIVE RELAPSED OR REFRACTORY CLASSICAL HODGKIN LYMPHOMA

Author

Johnson, Nathalie, primary, Lavie, David, additional, Borchmann, Peter, additional, Gregory, Gareth, additional, Herrera, Alex F., additional, Minuk, Leonard, additional, Vucinic, Vladan, additional, Armand, Philippe, additional, Avigdor, Abraham, additional, Gasiorowski, Robin, additional, Herishanu, Yair, additional, Keane, Colm, additional, Kuruvilla, John, additional, Marceau West, Rachel, additional, Pillai, Pallavi, additional, Marinello, Patricia, additional, and Timmerman, John, additional

Published
2023
Full Text
View/download PDF

24. Abstract CT052: A phase 1/2 randomized study of imvotamab monotherapy and in combination with loncastuximab tesirine in relapsed/refractory non-Hodgkin lymphomas

Author

Diefenbach, Catherine, primary, Kim, Won Seog, additional, Cheah, Chan, additional, Gopal, Ajay K., additional, Armand, Philippe, additional, Flinn, Ian, additional, Gregory, Gareth P., additional, Yoon, Sung-Soo, additional, Nastoupil, Loretta, additional, Lue, Jennifer, additional, Ribrag, Vincent, additional, Briones, Javier, additional, Salar-Silvestre, Antonio, additional, Sureda-Balari, Anna, additional, Ku, Matthew, additional, Cruz, Hans, additional, Thaler, Paul, additional, Qazi, Ibrahim, additional, Wei, Rachel, additional, Leabman, Maya, additional, Hernandez, Genevive, additional, Sison, Iris, additional, and Budde, Elizabeth, additional

Published
2023
Full Text
View/download PDF

25. Suppllementary Methods and Supplementary Figures 1-5 from BET Inhibition Induces Apoptosis in Aggressive B-Cell Lymphoma via Epigenetic Regulation of BCL-2 Family Members

Author

Hogg, Simon J., primary, Newbold, Andrea, primary, Vervoort, Stephin J., primary, Cluse, Leonie A., primary, Martin, Benjamin P., primary, Gregory, Gareth P., primary, Lefebure, Marcus, primary, Vidacs, Eva, primary, Tothill, Richard W., primary, Bradner, James E., primary, Shortt, Jake, primary, and Johnstone, Ricky W., primary

Published
2023
Full Text
View/download PDF

26. Data from BET Inhibition Induces Apoptosis in Aggressive B-Cell Lymphoma via Epigenetic Regulation of BCL-2 Family Members

Author

Hogg, Simon J., primary, Newbold, Andrea, primary, Vervoort, Stephin J., primary, Cluse, Leonie A., primary, Martin, Benjamin P., primary, Gregory, Gareth P., primary, Lefebure, Marcus, primary, Vidacs, Eva, primary, Tothill, Richard W., primary, Bradner, James E., primary, Shortt, Jake, primary, and Johnstone, Ricky W., primary

Published
2023
Full Text
View/download PDF

28. Figure S3 from AZD4320, A Dual Inhibitor of Bcl-2 and Bcl-xL, Induces Tumor Regression in Hematologic Cancer Models without Dose-limiting Thrombocytopenia

Author

Balachander, Srividya B., primary, Criscione, Steven W., primary, Byth, Kate F., primary, Cidado, Justin, primary, Adam, Ammar, primary, Lewis, Paula, primary, Macintyre, Terry, primary, Wen, Shenghua, primary, Lawson, Deborah, primary, Burke, Kathleen, primary, Lubinski, Tristan, primary, Tyner, Jeffrey W., primary, Kurtz, Stephen E., primary, McWeeney, Shannon K., primary, Varnes, Jeffrey, primary, Diebold, R. Bruce, primary, Gero, Thomas, primary, Ioannidis, Stephanos, primary, Hennessy, Edward J., primary, McCoull, William, primary, Saeh, Jamal C., primary, Tabatabai, Areya, primary, Tavana, Omid, primary, Su, Nancy, primary, Schuller, Alwin, primary, Garnett, Mathew J., primary, Jaaks, Patricia, primary, Coker, Elizabeth A., primary, Gregory, Gareth P., primary, Newbold, Andrea, primary, Johnstone, Ricky W., primary, Gangl, Eric, primary, Wild, Martin, primary, Zinda, Michael, primary, Secrist, J. Paul, primary, Davies, Barry R., primary, Fawell, Stephen E., primary, and Gibbons, Francis D., primary

Published
2023
Full Text
View/download PDF

29. Supplementary Figure 1 from The CDK9 Inhibitor Dinaciclib Exerts Potent Apoptotic and Antitumor Effects in Preclinical Models of MLL-Rearranged Acute Myeloid Leukemia

Author

Baker, Adele, primary, Gregory, Gareth P., primary, Verbrugge, Inge, primary, Kats, Lev, primary, Hilton, Joshua J., primary, Vidacs, Eva, primary, Lee, Erwin M., primary, Lock, Richard B., primary, Zuber, Johannes, primary, Shortt, Jake, primary, and Johnstone, Ricky W., primary

Published
2023
Full Text
View/download PDF

30. The clinical features, management and outcomes of lymphoma in pregnancy: A multicentre study by the Australasian Lymphoma Alliance

Author

Di Ciaccio, Pietro R., primary, Mills, Georgia, additional, Shipton, Michael J., additional, Campbell, Belinda, additional, Gregory, Gareth, additional, Langfield, Jenna, additional, Greenwood, Matthew, additional, McKeague, Sean, additional, Shanavas, Mohammad, additional, Eslick, Renee, additional, Kidson‐Gerber, Giselle, additional, Smallbone, Portia, additional, Tang, Catherine, additional, Morris, Kirk, additional, Bilmon, Ian, additional, Yannakou, Costas K., additional, Badoux, Xavier, additional, Berkahn, Leanne, additional, Farina, Sergio, additional, Mason, Kylie D., additional, Motum, Penelope, additional, Goss, Kathryn, additional, and Hamad, Nada, additional

Published
2023
Full Text
View/download PDF

33. Discovery of Mcl-1-specific inhibitor AZD5991 and preclinical activity in multiple myeloma and acute myeloid leukemia

Author

Tron, Adriana E., Belmonte, Matthew A., Adam, Ammar, Aquila, Brian M., Boise, Lawrence H., Chiarparin, Elisabetta, Cidado, Justin, Embrey, Kevin J., Gangl, Eric, Gibbons, Francis D., Gregory, Gareth P., Hargreaves, David, Hendricks, J. Adam, Johannes, Jeffrey W., Johnstone, Ricky W., Kazmirski, Steven L., Kettle, Jason G., Lamb, Michelle L., Matulis, Shannon M., Nooka, Ajay K., Packer, Martin J., Peng, Bo, Rawlins, Philip B., Robbins, Daniel W., Schuller, Alwin G., Su, Nancy, Yang, Wenzhan, Ye, Qing, Zheng, Xiaolan, Secrist, J. Paul, Clark, Edwin A., Wilson, David M., Fawell, Stephen E., and Hird, Alexander W.

Published
2018
Full Text
View/download PDF

35. UK Biobank: a globally important resource for cancer research

Author

Conroy, Megan C., primary, Lacey, Ben, additional, Bešević, Jelena, additional, Omiyale, Wemimo, additional, Feng, Qi, additional, Effingham, Mark, additional, Sellers, Jonathan, additional, Sheard, Simon, additional, Pancholi, Mahesh, additional, Gregory, Gareth, additional, Busby, John, additional, Collins, Rory, additional, and Allen, Naomi E., additional

Published
2022
Full Text
View/download PDF

36. Pharmacodynamics and Biomarker Correlates of Imvotamab (IGM-2323), the First-in-Class CD20xCD3 Bispecific IgM Antibody with Dual Mechanisms of Action, in Patients with Advanced B Cell Malignancies

Author

Hernandez, Genevive H., primary, So, John, additional, Logronio, Kathryn A., additional, Kotturi, Maya F., additional, Kim, Won Seog, additional, Armand, Philippe, additional, Cheah, Chan Y., additional, Gopal, Ajay K., additional, Flinn, Ian W., additional, Gregory, Gareth P., additional, Matasar, Matthew J., additional, Nastoupil, Loretta J., additional, Diefenbach, Catherine S., additional, Yoon, Sung-Soo, additional, Ku, Matthew, additional, Qazi, Ibrahim, additional, Leabman, Maya K., additional, Sison, Iris, additional, Keyt, Bruce A., additional, Takimoto, Chris H., additional, Manley, Thomas J., additional, and Budde, Elizabeth L., additional

Published
2022
Full Text
View/download PDF

37. Updated Results from an Open-Label Phase 1/2 Study of Favezelimab (anti-LAG-3) Plus Pembrolizumab in Relapsed or Refractory Classical Hodgkin Lymphoma after Anti-PD-1 Treatment

Author

Timmerman, John, primary, Lavie, David, additional, Johnson, Nathalie A., additional, Avigdor, Abraham, additional, Borchmann, Peter, additional, Andreadis, Charalambos, additional, Bazargan, Ali, additional, Gregory, Gareth P., additional, Keane, Colm, additional, Tsoran-Rosenthal, Inna, additional, Vucinic, Vladan, additional, Zinzani, Pier Luigi, additional, West, Rachel Marceau, additional, Pillai, Pallavi, additional, Nahar, Akash, additional, and Herrera, Alex F., additional

Published
2022
Full Text
View/download PDF

38. Updated Results from an Open-Label Phase 1/2 Study of Favezelimab (anti-LAG-3) Plus Pembrolizumab in Relapsed or Refractory Classical Hodgkin Lymphoma

Author

Johnson, Nathalie A., primary, Lavie, David, additional, Borchmann, Peter, additional, Gregory, Gareth P., additional, Herrera, Alex F., additional, Minuk, Leonard, additional, Vucinic, Vladan, additional, Armand, Philippe, additional, Avigdor, Abraham, additional, Gasiorowski, Robin, additional, Herishanu, Yair, additional, Keane, Colm, additional, Kuruvilla, John, additional, Palcza, John, additional, Pillai, Pallavi, additional, Nahar, Akash, additional, and Timmerman, John, additional

Published
2022
Full Text
View/download PDF

39. Phase 1b/2a Study of AZD4573 (CDK9i) and Acalabrutinib in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (r/r DLBCL): Results from Dose-Escalation

Author

Strati, Paolo, primary, Kim, Tae Min, additional, Danilov, Alexey V, additional, Cheah, Chan Y., additional, Yoon, Dok Hyun, additional, Jurczak, Wojciech, additional, Sharma, Shringi, additional, Yoon, Jeong Lim, additional, Arduini, Serena, additional, Saeh, Jamal, additional, Olsson, Richard F., additional, and Gregory, Gareth, additional

Published
2022
Full Text
View/download PDF

40. T058: Safety and Dose-Expansion Study of Combination Favezelimab (anti–LAG-3) Plus Pembrolizumab in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma Refractory to Anti–PD-1 Treatment

Author

Timmerman, John, primary, Lavie, David, additional, Johnson, Nathalie A., additional, Avigdor, Abraham, additional, Borchmann, Peter, additional, Andreadis, Charalambos, additional, Bazargan, Ali, additional, Gregory, Gareth, additional, Keane, Colm, additional, Tzoran, Inna, additional, Vucinic, Vladan, additional, Zinzani, Pier Luigi, additional, Zhang, Hong, additional, Pillai, Pallavi, additional, Nahar, Akash, additional, and Herrera, Alex F., additional

Published
2022
Full Text
View/download PDF

41. P061: Safety and Dose-Expansion Study of Combination Favezelimab (anti–LAG-3) Plus Pembrolizumab in Anti–PD-1–Naive Patients With Relapsed or Refractory Classical Hodgkin Lymphoma

Author

Borchmann, Peter, primary, Johnson, Nathalie A., additional, Lavie, David, additional, Gregory, Gareth, additional, Herrera, Alex F., additional, Minuk, Leonard, additional, Vucinic, Vladan, additional, Armand, Philippe, additional, Avigdor, Abraham, additional, Gasiorowski, Robin, additional, Herishanu, Yair, additional, Keane, Colm, additional, Kuruvilla, John, additional, Palcza, John, additional, Pillai, Pallavi, additional, Nahar, Akash, additional, and Timmerman, John, additional

Published
2022
Full Text
View/download PDF

44. Recommendation for TP53 mutation testing in newly diagnosed mantle cell lymphoma: a statement from working groups sponsored by the Victorian Comprehensive Cancer Centre

Author

Tam, Constantine S., primary, Gregory, Gareth P., additional, Ku, Matthew, additional, Fleming, Shaun, additional, Handunnetti, Sasanka M., additional, Lee, Denise, additional, Walker, Patricia, additional, Perkins, Andrew, additional, Lew, Thomas E., additional, Sirdesai, Shreerang, additional, Chua, Chong Chyn, additional, Gilbertson, Michael, additional, Lasica, Masa, additional, Anderson, Mary Ann, additional, Renwick, William, additional, Grigg, Andrew, additional, Patil, Sush, additional, Opat, Stephen, additional, Friebe, Adam, additional, Cooke, Rachel, additional, De Boer, Jasper, additional, Spencer, Andrew, additional, Ritchie, David, additional, Agarwal, Rishu, additional, and Blombery, Piers, additional

Published
2022
Full Text
View/download PDF

45. Abstract CT125: A phase 1/2 randomized study of IGM-2323 in relapsed/refractory non-Hodgkin lymphomas

Author

Nastoupil, Loretta, primary, Budde, Elizabeth, additional, Kim, Won Seog, additional, Gopal, Ajay, additional, Cheah, Chan, additional, Flinn, Ian, additional, Gregory, Gareth, additional, Matasar, Matthew, additional, Diefenbach, Catherine, additional, Ku, Matthew, additional, Yoon, Sung-Soo, additional, Qazi, Ibrahim, additional, Wei, Rachel, additional, Leabman, Maya, additional, Hernandez, Genevive, additional, Sison, Iris, additional, Keyt, Bruce, additional, Manley, Thomas, additional, and Armand, Phillipe, additional

Published
2022
Full Text
View/download PDF

46. Favezelimab (anti–LAG-3) plus pembrolizumab in patients with relapsed or refractory (R/R) classical Hodgkin lymphoma (cHL) after anti–PD-1 treatment: An open-label phase 1/2 study.

Author

Timmerman, John, primary, Lavie, David, additional, Johnson, Nathalie A., additional, Avigdor, Abraham, additional, Borchmann, Peter, additional, Andreadis, Charalambos, additional, Bazargan, Ali, additional, Gregory, Gareth, additional, Keane, Colm, additional, Inna, Tzoran, additional, Vucinic, Vladan, additional, Zinzani, Pier Luigi, additional, Zhang, Hong, additional, Pillai, Pallavi, additional, Marinello, Patricia, additional, and Herrera, Alex Francisco, additional

Published
2022
Full Text
View/download PDF

47. Outcomes by BCL2 and MYC expression and rearrangements in untreated diffuse large B-cell lymphoma (DLBCL) from the POLARIX trial.

Author

Morschhauser, Franck, primary, Jiang, Yanwen, additional, Jardin, Fabrice, additional, Herrera, Alex Francisco, additional, Sehn, Laurie Helen, additional, Herbaux, Charles, additional, Flowers, Christopher, additional, Phillips, Tycel Jovelle, additional, López Guillermo, Armando, additional, Magid Diefenbach, Catherine S., additional, Gregory, Gareth, additional, Kim, Austin Injae, additional, Barbui, Anna Maria, additional, Balasubramanian, Sandhya, additional, Harris, Will, additional, Hirata, Jamie, additional, Paulson, Joseph N., additional, Lee, Calvin, additional, and Lenz, Georg, additional

Published
2022
Full Text
View/download PDF

48. Favezelimab (anti–LAG-3) plus pembrolizumab in patients with anti–PD-1–naive relapsed or refractory (R/R) classical Hodgkin lymphoma (cHL): An open-label phase 1/2 study.

Author

Johnson, Nathalie A., primary, Lavie, David, additional, Borchmann, Peter, additional, Gregory, Gareth, additional, Herrera, Alex Francisco, additional, Minuk, Leonard, additional, Vucinic, Vladan, additional, Armand, Philippe, additional, Avigdor, Abraham, additional, Gasiorowski, Robin, additional, Herishanu, Yair, additional, Keane, Colm, additional, Kuruvilla, John, additional, Palcza, John, additional, Pillai, Pallavi, additional, Marinello, Patricia, additional, and Timmerman, John, additional

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results